Defining immunological biomarkers for head-and-neck-cancer: First Erlanger results of the prospective ImmunBioKHT trial
Background: Immunological biomarkers are becoming increasingly important in the classification and treatment of head and neck cancer (HNSCC). These markers include the expression of immune checkpoint molecules, but also various immune cell (sub)types. However, HNSCC not only interact with the immune [for full text, please go to the a.m. URL]
Institutions
- University Hospital Augsburg (DE)
- Universitätsklinikum Erlangen (DE)
- Saarland University (DE)
Publication Details
- Journal
- German Medical Science (German Research Foundation)
- Published
- 2024-09-16
- DOI
- https://doi.org/10.3205/24hnosw03
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00